摘要
Rimegepant是百时美施贵宝公司开发的口服小分子降钙素基因相关肽(Calcitonin gene receptor peptide,CGRP)受体拮抗剂。该药已于2020年3月被美国食品药品监督管理局(FDA)批准上市,被推荐用于治疗有或无先兆的偏头痛急性发作。与曲坦类药物不同,rimegepant没有血管收缩特性,安全性和耐受性更好,有良好的临床应用前景。
Rimegepant is an orally-administered small-molecule calcitonin gene receptor peptide(CGRP)antagonist developed by Bristol-Myers Squibb.The drug was launched with the permission of the US Food and Drug Administration(FDA)in March 2020 for the treatment of acute migraine with or without aura in adults.Unlike triptans,rimegepant has no vasoconstrictive properties,but has better safety and tolerability,which displays good prospect for its clinical application.
作者
袁秋慧
赵巧玲
张小飞
YUAN Qiu-hui;ZHAO Qiao-ling;ZHANG Xiao-fei(Jiangsu Chia Tai Fenghai Pharmaceutical Co.,Ltd.,Nanjing 210046,China;Lianyuangang Technical College,Lianyungang 222000,China;Shanxi University of Chinese Medicine,Shanxi Provincial Key Laboratory of Traditional Chinese Medicine and New Drug Research,Xianyang 712046,China)
出处
《实用药物与临床》
CAS
2021年第7期658-662,共5页
Practical Pharmacy and Clinical Remedies
基金
陕西省科学技术厅项目(2019SF-290)。
